TBH Global Asset Management LLC Has $2.73 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

TBH Global Asset Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 18,921 shares of the company’s stock after buying an additional 142 shares during the period. TBH Global Asset Management LLC’s holdings in Johnson & Johnson were worth $2,729,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. AMF Tjanstepension AB raised its holdings in shares of Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after purchasing an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $209,000. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $213,000. Swedbank AB raised its holdings in shares of Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after purchasing an additional 111,570 shares during the last quarter. Finally, Impact Partnership Wealth LLC raised its holdings in shares of Johnson & Johnson by 1.8% in the third quarter. Impact Partnership Wealth LLC now owns 7,160 shares of the company’s stock valued at $1,160,000 after purchasing an additional 126 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Barclays raised their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 1.7 %

Shares of Johnson & Johnson stock opened at $162.35 on Friday. The firm has a 50-day moving average of $148.93 and a 200-day moving average of $155.88. The stock has a market cap of $390.87 billion, a PE ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson’s payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.